YAP/TAZ at the Roots of Cancer.
暂无分享,去创建一个
Stefano Piccolo | S. Piccolo | Francesca Zanconato | M. Cordenonsi | Michelangelo Cordenonsi | Francesca Zanconato
[1] S. Bicciato,et al. YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins , 2016, EMBO reports.
[2] C. Eberhart,et al. Yes-Associated Protein 1 Is Widely Expressed in Human Brain Tumors and Promotes Glioblastoma Growth , 2011, Journal of neuropathology and experimental neurology.
[3] M. Yaffe,et al. Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation , 2014, Cell Death and Differentiation.
[4] D. Haber,et al. salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines , 2002, Cell.
[5] F. Zhou,et al. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder , 2013, BMC Cancer.
[6] B. Pruitt,et al. Mechanical strain induces E-cadherin–dependent Yap1 and β-catenin activation to drive cell cycle entry , 2015, Science.
[7] D. Moore,et al. Bile acids activate YAP to promote liver carcinogenesis. , 2013, Cell reports.
[8] Zhaoming Li,et al. TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. , 2015, Biochemical and biophysical research communications.
[9] Caroline H. Diep,et al. Down-Regulation of Yes Associated Protein 1 Expression Reduces Cell Proliferation and Clonogenicity of Pancreatic Cancer Cells , 2012, PloS one.
[10] D. Tuveson,et al. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. , 2011, The Journal of clinical investigation.
[11] Young Chul Kim,et al. Alternative Wnt Signaling Activates YAP/TAZ , 2015, Cell.
[12] Gi Jeong Kim,et al. Increased Expression of Yes-Associated Protein 1 in Hepatocellular Carcinoma with Stemness and Combined Hepatocellular-Cholangiocarcinoma , 2013, PloS one.
[13] M. Yaffe,et al. TAZ: a novel transcriptional co‐activator regulated by interactions with 14‐3‐3 and PDZ domain proteins , 2000, The EMBO journal.
[14] Q. Pan,et al. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. , 2013, Biochemical and biophysical research communications.
[15] J. Wrana,et al. Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer , 2015, Nature.
[16] G. M. Rudakova,et al. α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1 , 2011, Science Signaling.
[17] Z. Xuan,et al. Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma , 2008, Cell.
[18] I. Hariharan,et al. The Drosophila Mst Ortholog, hippo, Restricts Growth and Cell Proliferation and Promotes Apoptosis , 2003, Cell.
[19] H. Ohgaki,et al. Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas , 2015, Journal of neuropathology and experimental neurology.
[20] Joseph Rosenbluh,et al. KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.
[21] F. Camargo,et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance , 2011, Proceedings of the National Academy of Sciences.
[22] A. Asthagiri,et al. Matrix stiffening sensitizes epithelial cells to EGF and enables the loss of contact inhibition of proliferation , 2011, Journal of Cell Science.
[23] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[24] M. Giovannini,et al. Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators , 2013, Development.
[25] G. Mills,et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. , 2014, Anticancer research.
[26] S. Aerts,et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.
[27] M. Biffoni,et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.
[28] Valerie M. Weaver,et al. A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.
[29] H. Ji,et al. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin. , 2015, Cancer research.
[30] A. Wellstein,et al. Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma , 2014, Science Signaling.
[31] Y. Ip,et al. The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. , 2014, Developmental cell.
[32] J. Palacios,et al. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. , 2015, Endocrine-related cancer.
[33] D. McCollum,et al. Angiomotins link F-actin architecture to Hippo pathway signaling , 2014, Molecular biology of the cell.
[34] B. Thompson,et al. The Hippo pathway polarizes the actin cytoskeleton during collective migration of Drosophila border cells , 2013, The Journal of cell biology.
[35] Thomas D. Wu,et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.
[36] Randy L. Johnson,et al. Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size , 2011, Science.
[37] Patrick Cahan,et al. Hippo Pathway Activity Influences Liver Cell Fate , 2014, Cell.
[38] Sharon Gerecht,et al. Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis , 2015, Proceedings of the National Academy of Sciences.
[39] Q. Wang,et al. TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells , 2014, Molecular medicine reports.
[40] J. Inazawa,et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. , 2011, Carcinogenesis.
[41] H. Ji,et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex , 2014, Cell Research.
[42] Lei Zhang,et al. Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. , 2010, Developmental biology.
[43] M. Giovannini,et al. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. , 2003, Genes & development.
[44] U. Apte,et al. Deregulation of Hippo kinase signalling in Human hepatic malignancies , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[45] T. Xu,et al. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. , 1995, Development.
[46] Wen-Bin Li,et al. YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells , 2015, Molecular medicine reports.
[47] Yan Wang,et al. Clinical and prognostic significance of Yes-associated protein in colorectal cancer , 2013, Tumor Biology.
[48] Melinda M. Mulvihill,et al. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression , 2015, Science Signaling.
[49] D. Pan,et al. The hippo signaling pathway in development and cancer. , 2010, Developmental cell.
[50] Jun Yu,et al. Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis , 2011, Clinical Cancer Research.
[51] M. Rubin,et al. Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma , 2013, Genes, chromosomes & cancer.
[52] Shian Wu,et al. hippo Encodes a Ste-20 Family Protein Kinase that Restricts Cell Proliferation and Promotes Apoptosis in Conjunction with salvador and warts , 2003, Cell.
[53] Jie Pan,et al. Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. , 2012, Oncology reports.
[54] Andrew J Ewald,et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis , 2014, Genes & development.
[55] Songshu Meng,et al. YAP Enhances Autophagic Flux to Promote Breast Cancer Cell Survival in Response to Nutrient Deprivation , 2015, PloS one.
[56] W. Xiao,et al. Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors. , 2012, Chinese medical journal.
[57] May Yin Lee,et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity , 2015, Nature.
[58] Han-Sung Jung,et al. YAP and TAZ regulate skin wound healing. , 2014, The Journal of investigative dermatology.
[59] P J Bryant,et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. , 1995, Genes & development.
[60] G. Halder,et al. Modulating F‐actin organization induces organ growth by affecting the Hippo pathway , 2011, The EMBO journal.
[61] R. Virchow,et al. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre , 1861 .
[62] Pedro Gaspar,et al. Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila , 2011, Development.
[63] N. Tapon,et al. Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system , 2015, Proceedings of the National Academy of Sciences.
[64] R. Hynes,et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain , 2012, Proceedings of the National Academy of Sciences.
[65] S. Dedhar,et al. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase , 2013, Nature Communications.
[66] D. Calvisi,et al. The Hippo–Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis , 2010, Proceedings of the National Academy of Sciences.
[67] Kwok-Kin Wong,et al. A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway , 2013, Nature Cell Biology.
[68] S. Sheen-Chen,et al. Yes-associated protein is not an independent prognostic marker in breast cancer. , 2012, Anticancer research.
[69] G. Lou,et al. Clinical Significance of Yes-Associated Protein Overexpression in Cervical Carcinoma: The Differential Effects Based on Histotypes , 2013, International Journal of Gynecologic Cancer.
[70] P. Northcott,et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation , 2011, Oncogene.
[71] Jun O. Liu,et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.
[72] E. Oki,et al. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression. , 2015, Cancer research.
[73] Jill P. Mesirov,et al. β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2012, Cell.
[74] Arie Perry,et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.
[75] Jianbin Huang,et al. The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP , 2005, Cell.
[76] Jing Zhao,et al. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. , 2009, World journal of gastroenterology.
[77] J. George,et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.
[78] Randy L. Johnson,et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis , 2015, Nature Cell Biology.
[79] Stefano Monti,et al. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma , 2015, Molecular Cancer Research.
[80] C. Antonescu,et al. A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites , 2011, Genes, chromosomes & cancer.
[81] S. Dupont,et al. The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.
[82] Fei Li,et al. The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. , 2015, Urologic oncology.
[83] L. Zhu,et al. Tead and AP1 Coordinate Transcription and Motility. , 2016, Cell reports.
[84] Shan Jiang,et al. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.
[85] P. Northcott,et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. , 2009, Genes & development.
[86] R. Rosell,et al. TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma , 2014, BioMed research international.
[87] N. Carragher,et al. ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival , 2015, Cell reports.
[88] Bo Li,et al. The Role and Clinical Significance of Yes-Associated Protein 1 in Human Osteosarcoma , 2013, International journal of immunopathology and pharmacology.
[89] Li-juan Wang,et al. Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma , 2014, Journal of immunology research.
[90] Antonio Marchetti,et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies , 2015, Nature Genetics.
[91] Kang Zhang,et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. , 2014, Cancer cell.
[92] Jindan Yu,et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. , 2012, Genes & development.
[93] W. Hong,et al. TEADs Mediate Nuclear Retention of TAZ to Promote Oncogenic Transformation* , 2009, Journal of Biological Chemistry.
[94] T. Okano,et al. Hippo pathway regulation by cell morphology and stress fibers , 2011, Development.
[95] J. Llovet,et al. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. , 2015, Cell reports.
[96] Xiang-Dong Fu,et al. Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.
[97] M. Tsao,et al. TAZ is a novel oncogene in non-small cell lung cancer , 2011, Oncogene.
[98] E. Wagner,et al. Chronic inflammation imposes aberrant cell fate in regenerating epithelia through mechanotransduction , 2015, Nature Cell Biology.
[99] Hoguen Kim,et al. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. , 2012, Anticancer research.
[100] T. Pawson,et al. Yap- and Cdc42-Dependent Nephrogenesis and Morphogenesis during Mouse Kidney Development , 2013, PLoS genetics.
[101] J. Reis-Filho,et al. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein , 2016, Oncogene.
[102] Ganesh Rao,et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. , 2011, Genes & development.
[103] Daniel T. Montoro,et al. Tumor‐propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis , 2014, The EMBO journal.
[104] W. Jung,et al. Expression of Yes-associated protein (YAP) in metastatic breast cancer. , 2015, International journal of clinical and experimental pathology.
[105] A. Borczuk,et al. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells , 2015, Oncotarget.
[106] H. Fan,et al. YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients , 2014, PloS one.
[107] N. Tapon,et al. Sensing the local environment: actin architecture and Hippo signalling. , 2014, Current opinion in cell biology.
[108] J. Ajani,et al. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer , 2015, Clinical Cancer Research.
[109] William C Hines,et al. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.
[110] N. Sarvetnick,et al. Hippo Signaling Regulates Pancreas Development through Inactivation of Yap , 2012, Molecular and Cellular Biology.
[111] K. Guan,et al. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway , 2014, Oncogene.
[112] John T. Chang,et al. A gp130–Src–YAP module links inflammation to epithelial regeneration , 2015, Nature.
[113] Boon Chuan Low,et al. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth , 2014, FEBS letters.
[114] Nicola Elvassore,et al. Role of YAP/TAZ in mechanotransduction , 2011, Nature.
[115] Jing Zhao,et al. Overexpression of YAP1 is Correlated with Progression, Metastasis and Poor Prognosis in Patients with Gastric Carcinoma , 2014, Pathology & Oncology Research.
[116] S. Piccolo,et al. Eradicating tumor drug resistance at its YAP‐biomechanical roots , 2016, The EMBO journal.
[117] Hans Clevers,et al. Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.
[118] D. Calvisi,et al. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. , 2014, Gastroenterology.
[119] R. Drapkin,et al. YAP Induces High-Grade Serous Carcinoma in Fallopian Tube Secretory Epithelial Cells , 2015, Oncogene.
[120] R. M. Simpson,et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression , 2010, Proceedings of the National Academy of Sciences.
[121] M. Roncalli,et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. , 2014, Journal of hepatology.
[122] Jianmin Zhang,et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage , 2015, Oncogene.
[123] Shian Wu,et al. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. , 2013, Developmental cell.
[124] Jindan Yu,et al. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis , 2015, Cell Research.
[125] G. Riggins,et al. Yes-Associated Protein 1 Is Activated and Functions as an Oncogene in Meningiomas , 2012, Molecular Cancer Research.
[126] Jongshin Kim,et al. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation , 2016, The EMBO journal.
[127] Y. Sekido,et al. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness , 2015, Journal of neuropathology and experimental neurology.
[128] M. Sudol,et al. Yes-Associated Protein (YAP) Modulates Oncogenic Features and Radiation Sensitivity in Endometrial Cancer , 2014, PloS one.
[129] M. Wigler,et al. Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.
[130] Peijing Zhang,et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker , 2012, Nature Medicine.
[131] H. Ji,et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.
[132] P. Nelson,et al. ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. , 2015, Cancer cell.
[133] Nora C. Toussaint,et al. In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival , 2014, Pigment Cell & Melanoma Research.
[134] Q. Zeng,et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.
[135] L. Chin,et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.
[136] E. Nishida,et al. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β‐catenin signalling , 2012, The EMBO journal.
[137] Kun-Liang Guan,et al. Mechanisms of Hippo pathway regulation , 2016, Genes & development.
[138] R. Maria,et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy , 2014, Oncotarget.
[139] G. Halder,et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway , 2015, Nature Communications.
[140] G. Tonon,et al. RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS , 2014, Nature Medicine.
[141] M. Perez-Moreno,et al. Epithelial cell polarity, stem cells and cancer , 2011, Nature Reviews Cancer.
[142] Lin Mei,et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility , 2013, Proceedings of the National Academy of Sciences.
[143] Xiaoqian Zhang,et al. TAZ Expression as a Prognostic Indicator in Colorectal Cancer , 2013, PloS one.
[144] M. Giovannini,et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. , 2010, Developmental cell.
[145] Yoshimitsu Abiko,et al. An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.
[146] K. Song,et al. Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. , 2013, Histology and histopathology.
[147] A. Maitra,et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. , 2010, Genes & development.
[148] W. Jung,et al. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. , 2014, International journal of clinical and experimental pathology.
[149] H. Nojima,et al. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP , 2015, Genes & development.
[150] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[151] G. Feldmann,et al. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.
[152] Ju-Seog Lee,et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver , 2010, Proceedings of the National Academy of Sciences.
[153] M. Herlyn,et al. Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma , 2013, The Journal of investigative dermatology.
[154] Li-juan Wang,et al. Overexpression of YAP and TAZ Is an Independent Predictor of Prognosis in Colorectal Cancer and Related to the Proliferation and Metastasis of Colon Cancer Cells , 2013, PloS one.
[155] L. Yao,et al. Functional and Clinical Evidence That TAZ is a Candidate Oncogene in Hepatocellular Carcinoma , 2015, Journal of cellular biochemistry.
[156] Yonggang Zheng,et al. Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2 , 2013, Cell.
[157] Q. Ou,et al. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. , 2012, European journal of cancer.
[158] Jie Cheng,et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer , 2015, Molecular oncology.
[159] R. Jaenisch,et al. YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.
[160] S. Seshagiri,et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer , 2013, Nature Reviews Cancer.
[161] Qiang Liu,et al. TAZ regulates cell proliferation and epithelial–mesenchymal transition of human hepatocellular carcinoma , 2015, Cancer science.
[162] S. Bicciato,et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity , 2015, The EMBO journal.
[163] P. Singh,et al. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3 , 2015, Oncotarget.
[164] Seon-Young Kim,et al. A basal-like breast cancer-specific role for SRF–IL6 in YAP-induced cancer stemness , 2015, Nature Communications.
[165] G. G. Galli,et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. , 2014, Cancer cell.
[166] K. Song,et al. Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. , 2012, Anticancer research.
[167] D. Tomchick,et al. Structural and functional analysis of the YAP-binding domain of human TEAD2 , 2010, Proceedings of the National Academy of Sciences.
[168] X. Matías-Guiu,et al. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer , 2015, Modern Pathology.
[169] Piyush B. Gupta,et al. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. , 2014, Cell reports.
[170] S. Hilsenbeck,et al. Hippo pathway effector Yap is an ovarian cancer oncogene. , 2010, Cancer research.
[171] M. Sudol,et al. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. , 1994, Oncogene.
[172] P. Yuan,et al. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression , 2014, Oncogene.
[173] S. Bicciato,et al. Role of TAZ as Mediator of Wnt Signaling , 2012, Cell.
[174] K. Guan,et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway , 2015, Nature Cell Biology.
[175] Robert P. Jenkins,et al. Mechano-transduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer associated fibroblasts , 2013, Nature Cell Biology.
[176] A. Rosato,et al. Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.
[177] Ju-Seog Lee,et al. Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients , 2014, Clinical Cancer Research.
[178] Antonio Rosato,et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.
[179] Gang Liang,et al. Expression of Yes-Associated Protein in Cervical Squamous Epithelium Lesions , 2014, International Journal of Gynecologic Cancer.
[180] Hidemi Ito,et al. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth , 2012, The Journal of experimental medicine.
[181] C. Mein,et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast , 2008, Cell Death and Differentiation.
[182] Jeannie T. Lee,et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. , 2009, Cancer cell.
[183] G. Merlino,et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. , 2014, Cancer cell.
[184] Clare M. Waterman,et al. YAP Nuclear Localization in the Absence of Cell-Cell Contact Is Mediated by a Filamentous Actin-dependent, Myosin II- and Phospho-YAP-independent Pathway during Extracellular Matrix Mechanosensing* , 2016, The Journal of Biological Chemistry.
[185] S. Lowe,et al. Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma , 2009, Cancer.
[186] W. Hong,et al. Structural basis of YAP recognition by TEAD4 in the hippo pathway. , 2010, Genes & development.
[187] Y. Kondo,et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. , 2011, Cancer research.
[188] D. Placantonakis,et al. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells , 2015, Nature Communications.
[189] Nicholas Y. Palermo,et al. The Hippo Pathway Effector YAP Regulates Motility, Invasion, and Castration-Resistant Growth of Prostate Cancer Cells , 2015, Molecular and Cellular Biology.
[190] I. Clay,et al. YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers , 2015, PLoS genetics.
[191] A. Maitra,et al. β-Catenin destruction complex-independent regulation of Hippo–YAP signaling by APC in intestinal tumorigenesis , 2015, Genes & development.
[192] David M. Thomas,et al. The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.
[193] P. Hupé,et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. , 2014, Neuro-oncology.
[194] P. Lambert,et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression , 2015, EMBO molecular medicine.
[195] J. Ajani,et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. , 2014, Cancer research.
[196] S. Lowe,et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma , 2011, Oncogene.
[197] P. Chuang,et al. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth. , 2015, Developmental biology.
[198] Daniel G. Anderson,et al. Loss of α-catenin elicits a cholestatic response and impairs liver regeneration , 2014, Scientific Reports.
[199] O. Kirak,et al. Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation , 2011, Cell.
[200] M. Greene,et al. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis , 2015, Scientific Reports.
[201] S. Vandenberg,et al. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. , 2008, Neoplasia.
[202] Hongyun Zhao,et al. Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[203] Hang He,et al. Two-signal requirement for growth-promoting function of Yap in hepatocytes , 2015, eLife.
[204] E. Wang,et al. Overexpression of yes‐associated protein contributes to progression and poor prognosis of non‐small‐cell lung cancer , 2010, Cancer science.
[205] E. Ballestar,et al. Autophagy maintains stemness by preventing senescence , 2016, Nature.
[206] Jiandie D. Lin,et al. TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.
[207] S. Arron,et al. αE-catenin inhibits a Src–YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway , 2016, Genes & development.
[208] N. Elvassore,et al. A Mechanical Checkpoint Controls Multicellular Growth through YAP/TAZ Regulation by Actin-Processing Factors , 2013, Cell.
[209] Xiao Han,et al. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. , 2015, Structure.
[210] Nam‐Gyun Kim,et al. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components , 2011, Proceedings of the National Academy of Sciences.
[211] Li Li,et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.
[212] Valerie M. Weaver,et al. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.
[213] F. van Roy,et al. Alpha-Catenins Control Cardiomyocyte Proliferation by Regulating Yap Activity , 2015, Circulation research.
[214] B. Mao,et al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma , 2014, Oncogene.
[215] Erik Sahai,et al. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.
[216] E. Olson,et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex , 2014, The Journal of experimental medicine.
[217] N. Yang,et al. Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis , 2015, Cell cycle.
[218] J. Asara,et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. , 2014, Cell reports.
[219] Toby C. Cornish,et al. Yes-Associated Protein Regulates the Hepatic Response After Bile Duct Ligation , 2012, Hepatology.
[220] G. G. Galli,et al. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. , 2015, Molecular cell.
[221] Stefano Piccolo,et al. Transduction of mechanical and cytoskeletal cues by YAP and TAZ , 2012, Nature Reviews Molecular Cell Biology.
[222] E. Fuchs,et al. Plasticity of epithelial stem cells in tissue regeneration , 2014, Science.
[223] Shuji Ogino,et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP , 2012, Nature.
[224] Giuseppe Basso,et al. YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.